|
rs10748835
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data promotes the realization that AS3MT 35587 (rs11191453), 35991 (rs10748835), especially their joint genotypes 35991 (rs10748835) AA / 35587 (rs11191453) TC+CC, is a novel predictive biomarker for the therapeutic efficacy of As<sub>2</sub>O<sub>3</sub> in the treatment of APL.
|
31330140 |
2019 |
|
rs11191453
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
Our data promotes the realization that AS3MT 35587 (rs11191453), 35991 (rs10748835), especially their joint genotypes 35991 (rs10748835) AA / 35587 (rs11191453) TC+CC, is a novel predictive biomarker for the therapeutic efficacy of As<sub>2</sub>O<sub>3</sub> in the treatment of APL.
|
31330140 |
2019 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Autistic Disorder
|
|
0.010 |
GeneticVariation |
BEFREE |
Therefore, this family-based association study was performed in 640 Chinese Han autism trios to investigate the association between autism and 7 SNPs with genome-wide significance in previous GWAS (rs4307059 near MSNP1AS, rs4141463 in MACROD2, rs2535629 in ITIH3, rs11191454 in AS3MT, rs1625579 in MIR137HG, rs11191580 in NT5C2, and rs1409313 in CUEDC2).
|
30610940 |
2019 |
|
rs11191438
|
AS3MT;BORCS7-ASMT
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
AS3MT rs11191438 (C > G) G/G genotype, AS3MT rs10748835 (A > G) G/G genotype, and AS3MT rs1046778 (C > T) T/T genotype were found to be related to BC risk, where the odds ratio (OR) (95% CI) was 0.50 (0.31-0.82), 0.49 (0.30-0.79), and 0.54 (0.36-0.80), respectively.
|
29669044 |
2018 |
|
rs11191438
|
AS3MT;BORCS7-ASMT
|
Malignant neoplasm of urinary bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
AS3MT rs11191438 (C > G) G/G genotype, AS3MT rs10748835 (A > G) G/G genotype, and AS3MT rs1046778 (C > T) T/T genotype were found to be related to BC risk, where the odds ratio (OR) (95% CI) was 0.50 (0.31-0.82), 0.49 (0.30-0.79), and 0.54 (0.36-0.80), respectively.
|
29669044 |
2018 |
|
rs11191438
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
AS3MT rs11191438 (C > G) G/G genotype, AS3MT rs10748835 (A > G) G/G genotype, and AS3MT rs1046778 (C > T) T/T genotype were found to be related to BC risk, where the odds ratio (OR) (95% CI) was 0.50 (0.31-0.82), 0.49 (0.30-0.79), and 0.54 (0.36-0.80), respectively.
|
29669044 |
2018 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
In this article, the associations among urinary arsenic profiles, hematological and biochemical values, and 3 AS3MT genotypes (rs3740392, rs3740390, and rs11191439) were evaluated in 50 APL patients treated with arsenic trioxide (As2O3).
|
30376134 |
2018 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Malignant neoplasm of urinary bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs11191454
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs3740390
|
AS3MT;BORCS7-ASMT
|
Acute Promyelocytic Leukemia
|
|
0.010 |
GeneticVariation |
BEFREE |
These results indicate that inherent genetic information of the AS3MT rs3740390 genotypes is a novel predicted or evaluated target for As2O3-induced side effects and therapeutic efficacy for the treatment of APL.
|
30376134 |
2018 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Malignant neoplasm of urinary bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
The polymorphisms of AS3MT rs11191438, AS3MT rs10748835, and AS3MT rs1046778 were related to the risk of BC and UTUC, while the polymorphisms of AS3MT rs3740393, AS3MT rs11191453, and AS3MT rs11191454 were associated with arsenic methylation capacity.
|
29859237 |
2018 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation |
BEFREE |
For example, compared to wildtypes, individuals carrying minor alleles in AS3MT rs3740393 had lower %MMA (mean difference = -1.9%, 95% CI: -3.3, -0.4), higher %DMA (mean difference = 4.0%, 95% CI: 1.5, 6.5), and lower odds ratios for bladder (OR = 0.3; 95% CI: 0.1-0.6) and lung cancer (OR = 0.6; 95% CI: 0.2-1.1).
|
28640505 |
2017 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Malignant neoplasm of lung
|
|
0.010 |
GeneticVariation |
BEFREE |
For example, compared to wildtypes, individuals carrying minor alleles in AS3MT rs3740393 had lower %MMA (mean difference = -1.9%, 95% CI: -3.3, -0.4), higher %DMA (mean difference = 4.0%, 95% CI: 1.5, 6.5), and lower odds ratios for bladder (OR = 0.3; 95% CI: 0.1-0.6) and lung cancer (OR = 0.6; 95% CI: 0.2-1.1).
|
28640505 |
2017 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Primary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation |
BEFREE |
For example, compared to wildtypes, individuals carrying minor alleles in AS3MT rs3740393 had lower %MMA (mean difference = -1.9%, 95% CI: -3.3, -0.4), higher %DMA (mean difference = 4.0%, 95% CI: 1.5, 6.5), and lower odds ratios for bladder (OR = 0.3; 95% CI: 0.1-0.6) and lung cancer (OR = 0.6; 95% CI: 0.2-1.1).
|
28640505 |
2017 |
|
rs3740393
|
AS3MT;BORCS7-ASMT
|
Meningomyelocele
|
|
0.010 |
GeneticVariation |
BEFREE |
Drinking water inorganic arsenic concentration was associated with increased risk of myelomeningocele for participants with 4 of the 14 studied single-nucleotide polymorphisms in genes involved in folate metabolism: the AA/AG genotype of rs2236225 (MTHFD1), the GG genotype of rs1051266 (SLC19A1), the TT genotype of rs7560488 (DNMT3A), and the GG genotype of rs3740393 (AS3MT) with adjusted odds ratio of 1.13, 1.31, 1.20, and 1.25 for rs2236225, rs1051266, rs7560488, and rs3740393, respectively.
|
26250961 |
2015 |
|
rs10748835
|
AS3MT;BORCS7-ASMT;LOC107984265
|
Hyperlipidemia
|
|
0.010 |
GeneticVariation |
BEFREE |
The current study was to determine if coronary heart disease, hypertension, and hyperlipidemia were associated with low-level arsenic exposure and AS3MT gene single nucleotide polymorphism (SNP) A35991G (rs10748835) in rural Texas.
|
22341486 |
2012 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Malignant neoplasm of urinary bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Malignant neoplasm of urinary bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Bladder Neoplasm
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |
|
rs11191439
|
AS3MT;BORCS7-ASMT
|
Carcinoma of bladder
|
|
0.010 |
GeneticVariation |
BEFREE |
Individuals with one or more copies of the C allele in rs11191439 (the Met287Thr polymorphism) had an elevated risk of bladder cancer (OR = 1.17; 95% CI = 1.04-1.32 per 1 μg/L increase in average exposure).
|
22747749 |
2012 |